Artículo de Revisión
183
Obesidad y enfe rmedad inf lama toria in tes tina l - C. Estay H. et al.
Morphological and inflammatory changes
in visceral adipose tissue during obesity.
Endocr Pathol 2014; 25: 93-101.
24.- Marcadenti A, de Abreu-Silva EO.
Different adipose tissue depots:
Metabolic implications and effects of
surgical removal. Endocrinol Nutr 2015;
62: 458-64.
25.- Wang G, Stange EF, Wehkamp J. Hostmicrobe
interaction: mechanisms of
defensin deficiency in Crohn’s disease.
Expert Rev Anti Infect Ther 2007; 5:
1049-57.
26.- De Filippo C, Cavalieri D, Di Paola M,
Ramazzotti M, Poullet JB, Massart S,
et al. Impact of diet in shaping gut
microbiota revealed by a comparative
study in children from Europe and rural
Africa. Proc Natl Acad Sci USA 2010;
107: 14691-6.
27.- Carbo AI, Reddy T, Gates T, Vesa T,
Thomas J, González E. The most
characteristic lesions and radiologic signs
of Crohn disease of the small bowel: air
enteroclysis, MDCT, endoscopy, and
pathology. Abdom Imaging 2014; 39:
215-34.
28.- Büning C, von Kraft C, Hermsdorf M,
Gentz E, Wirth EK, Valentini L, et al.
Visceral adipose tissue in patients with
Crohn’s Disease correlates with disease
activity, inflammatory markers, and
outcome. Inflamm Bowel Dis 2015; 21:
2590-7.
29.- Zulian A, Cancello R, Micheletto G,
Gentilini D, Gilardini L, Danelli P, et al.
Visceral adipocytes: old actors in obesity
and new protagonists in Crohn’s disease?
Gut 2012; 61: 86-94.
30.- Gómez-Ambrosi J, González-Crespo I,
Catalán V, Rodríguez A, Moncada R,
Valentí V, et al. Clinical usefulness
of abdominal bioimpedance (ViScan)
in the determination of visceral fat
and its application in the diagnosis
and management of obesity and its
comorbidities. Clin Nutr 2017; S0261-
5614 (17): 30034-1.
31.- Garvey WT, Mechanick JI, Brett EM,
Garber AJ, Hurley DL, Jastreboff AM,
et al. American association of clinical
endocrinologists and American college
of endocrinology comprehensive clinical
practice guidelines for medical care of
patients with obesity. Endocr Pract 2016;
22 Suppl 3: 1-203.
32.- Blain A, Cattan S, Beaugerie L,
Carbonnel F, Gendre JP, Cosnes J.
Crohn’s disease clinical course and
severity in obese patients. Clin Nutr
2002; 21: 51-7.
33.- Hass DJ, Brensinger CM, Lewis JD,
Lichtenstein GR. The impact of increased
body mass index on the clinical course
of Crohn’s disease. Clin Gastroenterol
Hepatol 2006; 4: 482-8.
34.- Pringle PL, Stewart KO, Peloquin JM,
Sturgeon HC, Nguyen D, Sauk J, et al.
Body mass index, genetic susceptibility,
and risk of complications among
individuals with Crohn’s Disease.
Inflamm Bowel Dis 2015; 21: 2304-10.
35.- Seminerio JL, Koutroubakis IE, Ramos-
Rivers C, Hashash JG, Dudekula A,
Regueiro M, et al. Impact of obesity
on the management and clinical course
of patients with inflammatory bowel
disease. Inflamm Bowel Dis 2015; 21:
2857-63.
36.- Flores A, Burstein E, Cipher DJ,
Feagins LA. Obesity in inflammatory
bowel disease: a marker of less severe
disease. Dig Dis Sci 2015; 60: 2436-45.
37.- Van Der Sloot KW, Joshi AD, Bellavance
DR, Gilpin KK, Stewart KO, Lochhead
P, et al. Visceral adiposity, genetic
susceptibility, and risk of complications
among individuals with Crohn’s Disease.
Inflamm Bowel Dis 2017; 23: 82-8.
38.- Uko V, Vortia E, Achkar JP, Karakas P,
Fiocchi C, Worley S, et al. Impact of
abdominal visceral adipose tissue on
disease outcome in pediatric Crohn’s
disease. Inflamm Bowel Dis 2014; 20:
2286-91.
39.- Erhayiem B, Dhingsa R, Hawkey CJ,
Subramanian V. Ratio of visceral to
subcutaneous fat area is a biomarker
of complicated Crohn’s disease. Clin
Gastroenterol Hepatol 2011; 9: 684-7.
40.- Estay C, Simian D, Lubascher J,
Figueroa C, O’Brien A, Quera R.
Ionizing radiation exposure in patients
with inflammatory bowel disease: are
we overexposing our patients? J Dig Dis
2015; 16: 83-9.
41.- Poon SS, Asher R, Jackson R,
Kneebone A, Collins P, Probert C,
et al. Body mass index and smoking
affect thioguanine nucleotide levels in
inflammatory bowel disease. J Crohns
Colitis 2015; 9: 640-6.
42.- Harper JW, Sinanan MN, Zisman TL.
Increased body mass index is associated
with earlier time to loss of response to
infliximab in patients with inflammatory
bowel disease. Inflamm Bowel Dis 2013;
19: 2118-24.
43.- Bhalme M, Sharma A, Keld R, Willert R,
Campbell S. Does weight-adjusted antitumour
necrosis factor treatment favour
obese patients with Crohn’s disease?
Eur J Gastroenterol Hepatol 2013; 25:
543-9.
44.- Bultman E, de Haar C, van Liere-
Baron A, Verhoog H, West RL,
Kuipers EJ, et al. Predictors of
dose escalation of adalimumab in a
prospective cohort of Crohn’s disease
patients. Aliment Pharmacol Ther 2012;
35: 335-41.
45.- Nakahigashi M, Yamamoto T. Increases
in body mass index during infliximab
therapy in patients with Crohn’s disease:
an open label prospective study. Cytokine
2011; 56: 531-5.
46.- Peyrin-Biroulet L, Loftus EV Jr,
Colombel JF, Sandborn WJ. The
natural history of adult Crohn’s disease
in population-based cohorts. Am J
Gastroenterol 2010; 105: 289-97.
47.- Onali S, Calabrese E, Petruzziello C,
Lolli E, Ascolani M, Ruffa A, et al.
Post-operative recurrence of Crohn’s
disease: A prospective study at 5 years.
Dig Liver Dis 2016; 48: 489-94.
48.- Li Y, Zhu W, Gong J, Zhang W, Gu L,
Guo Z, Cao, et al. Visceral fat area is
associated with a high risk for early
postoperative recurrence in Crohn’s
disease. Colorectal Dis 2015; 17:
225-34.
49.- Holt DQ, Moore GT, Strauss BJ,
Hamilton AL, De Cruz P, Kamm MA.
Visceral adiposity predicts post-
operative Crohn’s disease recurrence.
Aliment Pharmacol Ther 2017; 45:
1255-64.
50.- Malik TA, Manne A, Oster RA,
Eckhoff A, Inusah S, Gutiérrez AM.
Obesity is associated with poor
surgical outcome in Crohn’s Disease.
Gastroenterology Res 2013; 6: 85-90.
51.- Ding Z, Wu XR, Remer EM, Lian L,
Stocchi L, Li Y, McCullough A, et al.
Association between high visceral fat
area and postoperative complications in
patients with Crohn’s disease following
Gastroenterol. latinoam 2017; Vol 28, Nº 3: 177-184